Portfolio
SVLSF III closed in 2003 with total commitments of $393 million (plus $8 million of co-investments committed by partners and individuals affiliated with SVLS).
As at 31 December 2012 the Fund had invested $407 million in 39 portfolio companies.
39 matching investments found
| Company | Country | Stage | Sector | Year |
|---|---|---|---|---|
 Alantos Pharmaceuticals | US | Early Stage | Biotechnology Biopharmaceuticals | 2003 |
| Sold to Amgen in June 2007. Alantos was a chemistry-driven company seeking to discover and develop drugs targeted at osteoarthritis and inflammatory processes. The company attempts to fast follow others to reduce risk. | ||||
 Alba Therapeutics | US | Early Stage | Biotechnology Biopharmaceuticals | 2005 |
| Alba based in Baltimore, MD, is focused on the development and commercialization of pharmaceuticals for the treatment of inflammatory and immune mediated diseases. Alba's technology provides the ability to transiently open or close internal barriers such as the intestinal mucosa. Alba is applying its technology to develop treatments for celiac disease and other autoimmune conditions. | ||||
 Alinea Pharmaceuticals | US | Expansion | Biotechnology Biopharmaceuticals | 2005 |
| Dedicated to developing and commercializing pharmaceuticals for the treatment of diabetes and related metabolic disorders. | ||||
 Allegiance Hospice Group | US | Start Up | Healthcare Services | 2005 |
| Allegiance Hospice is based in Lowell, MA, focused on providing hospice services to patients primarily in long- term care facilities within the New England market. | ||||
 AqueSys | US | Early Stage | Medical Devices Instrumentation | 2006 |
| AqueSys is based in Duluth, GA; AqueSys (TIF company) is developing an innovative approach to reducing intra-ocular pressure to treat glaucoma. | ||||
 Archemix | US | Early Stage | Biotechnology Biopharmaceuticals | 2002 |
| Archemix, based in Cambridge, MA, is developing nucleic acid aptamers for therapeutic indications, building on a broad IP portfolio acquired from Gilead/Nexstar. | ||||
 Avera Pharmaceuticals | US | Early Stage | Biotechnology Biopharmaceuticals | 2004 |
| Avera is based in San Diego, CA and focused on the development of small molecule drugs for the treatment of diseases affecting the central nervous system (CNS). Key programs are Alzheimer's disease, schizophrenia associated cognition deficits, IBS, and OAB, and developing an ultra-short acting anaesthesia compound. | ||||
 Celldex/Lorantis | UK | Seed | Biotechnology Biopharmaceuticals | 2003 |
| Celldex merged with the quoted company Avant Immunotherapeutics (ticker:'AVAN') in March 2008. Celldex, formerly a wholly owned subsidiary of Medarex Inc., merged with Lorantis Ltd in 2005. Celldex pursues immunological approaches to the treatment of cancers, infectious disease and immunological disorders. | ||||
 Cellutions | US | Seed | Medical Devices Instrumentation | 2004 |
| Cellutions (TIF Company), based in Duluth, GA, (is developing a minimally invasive approach for addressing cellulite and its appearance on the skin. | ||||
 CHF Solutions | US | Expansion | Medical Devices Instrumentation | 2005 |
| CHF is based in Brooklyn Park, MN and has developed a mechanical pump/filter system to remove excess fluid from patients with acute de-compensated congestive heart failure. The product has US 510k clearance and is CE marked for both in-patient hospital care and out-patient clinic use. | ||||
 Concentric Medical | US | Expansion | Medical Devices Instrumentation | 2003 |
| Concentric is based in Mountain View, CA and is designing and developing products to open the blood pathway for ischemic stroke patients. Their first device, the MERCI Retriever®, removes clots associated with ischemic strokes. | ||||
 CoreLab Partners | US | Expansion | Healthcare Services | 2004 |
| CoreLab Partners, based in Princeton, NJ, provides ECG core lab services related to cardiac safety testing for global clinical trials. Formerly known as Medifacts International. | ||||
 Delenex Therapeutics | Switzerland | Early Stage | Biotechnology Biopharmaceuticals | 2009 |
| Delenex is a spin out from ESBATech, an investment that was divested in 2009. The business focuses on research and development in its antibody fragments for topical delivery. | ||||
 Dynogen Pharmaceuticals | US | Early Stage | Biotechnology Biopharmaceuticals | 2004 |
| Dynogen is a neuroscience-based company focused on genito-urinary (GU) and gastro-intestinal (GI) disorders. The company is using its knowledge of neurology and GU/GI disorders to build a pipeline of clinical candidates. | ||||
 EBR Systems | US | Early Stage | Medical Devices Instrumentation | 2005 |
| EBR Systems is developing a wireless cardiac stimulation device (WiCS) to compete in the cardiac resynchronization therapy space for treatment of congestive heart failure. | ||||
 Entellus | US | Early Stage | Medical Devices Instrumentation | 2006 |
| Entellus has developed a novel balloon treatment for chronic sinusitis. | ||||
 ESBATech | Switzerland | Early Stage | Biotechnology Biopharmaceuticals | 2006 |
| Sold to Alcan in September 2009. ESBATech is a preclinical stage drug discovery company that intends to refocus the business to build a world class Ophthalmology company on the back of an attractive, proprietary antibody fragment platform which can deliver uniquely stable, soluble and monomeric fragments and compelling data on penetration of these fragments into the eye following topical treatment. | ||||
 Eunoe | US | Expansion | Medical Devices Instrumentation | 2003 |
| Eunoe was a treatment of neurological disorders through cerebrospinal fluid management (CSF). | ||||
 GlycoFi | US | Start Up | Biotechnology Biopharmaceuticals | 2002 |
| Sold to Merck in May 2006. GlycoFi was a production and engineering of therapeutics proteins. | ||||
 Gyros | Sweden | Start Up | Medical Devices Instrumentation | 2002 |
| Gyros, located in Uppsala, Sweden, has developed a proprietary microfluidics technology for processing and analysis of proteins and blood samples. Laboratory processes are integrated into a client specific disc (CD) format. The CD is processed and its contents analysed on software controlled instrumentation. | ||||
 Ikano Therapeutics | US | Early Stage | Biotechnology Biopharmaceuticals | 2006 |
| ITI is a specialty pharmaceutical company focused on developing innovative, nasally delivered pharmaceutical products with a particular focus on drugs treating pain and CNS-related disorders for which there is proven, unmet patient need. | ||||
 Insulet | US | Start Up | Medical Devices Instrumentation | 2001 |
| Insulet based in Bedford, MA, Insulet is designing and developing products that provide superior treatment for people with diabetes. The Company's first commercial product is a wireless 3-day insulin pump. | ||||
 LipoSonix | US | Seed | Medical Devices Instrumentation | 2001 |
| LipoSonix based in Bothell, WA, was developing a product to use non-invasive, high intensity focused ultrasound to ablate unwanted subcutaneous cells as a non-invasive alternative to liposuction for body sculpting. Funded through the innovation factory. | ||||
 Lux Biosciences | US | Seed | Biotechnology Biopharmaceuticals | 2006 |
| Lux is developing drugs for ophthalmic diseases. Their lead product is LX211, an oral drug for the treatment of uveitis. | ||||
 Mpex Pharmaceuticals | US | Early Stage | Biotechnology Biopharmaceuticals | 2005 |
| Mpex based in San Diego, CA, is focused on the discovery and development of new-antibacterial drugs that meet the growing clinical need created by multi-drug resistant bacteria. Mpex has identified several approaches to increase the effectiveness of existing antibiotics and decrease the incidence of drug resistance to these antibiotics. Mpex's first product will be an inhaled antibiotic for serious lung infections. | ||||
 NeoVista | US | Seed | Medical Devices Instrumentation | 2003 |
| NeoVista, based in Mountain View, CA, is developing a unique technology to arrest vascular proliferation in the back of the eye with localized radiation for treatment of wet age related macular degeneration (AMD). | ||||
 Neurotech | US | Early Stage | Biotechnology Biopharmaceuticals | 2006 |
| Neurotech based in Lincoln, RI, has developed an encapsulated cell therapy for the delivery of therapeutic proteins in retinal diseases. The first product is ciliary neurothrophic factor (CNTF) for retinitis pigmentosa and age-related macular degeneration (geographic atrophy). | ||||
 NovaLign | US | Seed | Medical Devices Instrumentation | 2005 |
| NovaLign, based in Duluth, GA, is developing a minimally invasive implant for long bone fixation. Formerly known as OsteoLign. | ||||
 Patient Care | US | Buyout | Healthcare Services | 2002 |
| Patient Care based in Orange, NJ, is one of the largest independent home health agencies. | ||||
 PowderMed | UK | Early Stage | Biotechnology Biopharmaceuticals | 2004 |
| Sold to Pfizer in October 2006. PowderMed developed therapeutic DNA vaccines in the areas of chronic viral diseases and cancer. | ||||
 ReShape | US | Seed | Medical Devices Instrumentation | 2005 |
| ReShape is a seed stage project within the Intersect Partners incubator developing an endoscopically placed device for the treatment of obesity. | ||||
 Rinat Neuroscience | US | Early Stage | Biotechnology Biopharmaceuticals | 2003 |
| Sold to Pfizer in April 2006. Rinat developed proteins for the treatment of diseases and disorders of the nervous system. | ||||
 Sadra Medical | US | Seed | Medical Devices Instrumentation | 2009 |
| Sadra Medical has developed a second generation Percutaneous Aortic Valve Replacement (PAVR) implant and delivery system for the treatment of aortic stenosis. | ||||
 Sapphire Therapeutics | US | Early Stage | Biotechnology Biopharmaceuticals | 2004 |
| Acquired by Helsinn in February 2009. Helsinn is developing small molecule drugs based on the biology of ghrelin,a gut peptide known to stimulate appetite. The lead compound is in Ph II for cancer cachexia; a second compound has completed an initial clinical study and is moving toward Ph II for post-operative ileus. Additional indications are being explored for follow-on compounds. Formerly known as Rejuvenon. | ||||
 Socios Mayores en Salud | US | Expansion | Healthcare Services | 2006 |
| Socios Mayores en Salud provides health insurance to seniors in Puerto Rico through a Medicare Advantage plan that operates similar to traditional managed care organizations. | ||||
 Spinal Kinetics | US | Early Stage | Medical Devices Instrumentation | 2005 |
| Spinal Kinetics, based in Sunnyvale, CA, is developing artificial discs for use in the cervical and lumbar spine. | ||||
 Sutro Biopharma, Inc | US | Early Stage | Biotechnology Biopharmaceuticals | 2006 |
| Sutro Biopharma's mission is to enable the production of low-cost, high quality rapidly developed protein pharmaceuticals and innovative vaccines that cannot be manufactured by existing technologies. Previously known as Fundamental Applied Biology's (FAB). | ||||
 Synarc | US | Late Stage | Healthcare Services | 2004 |
| Synarc provides centralized medical imaging services and international subject-recruitment facilities dedicated exclusively to global clinical trials. | ||||
 US Renal Care | US | Expansion | Healthcare Services | 2005 |
| US Renal Care(USRC) based in Dallas, TX, provides dialysis services to patients with end stage renal disease (ESRD) through the ownership and management of freestanding dialysis clinics. The company partners with local nephrologists in secondary markets underserved by dialysis consolidators. | ||||